Navigation Links
Cancer biomarker -- detectable by blood test -- could improve prostate cancer detection
Date:8/8/2011

CINCINNATIA new study supports the use of a DNA-based "biomarker" blood test as a complement to the prostate-specific antigen (PSA) test currently offered to screen men for prostate cancer. University of Cincinnati (UC) researchers report their findings online ahead of print in the British Journal of Cancer.

Researchers conducted a meta-analysis of existing published data related to DNA methylation in bodily fluids. The goal was to evaluate a specific cancer biomarkerknown as GSTP1as a screening tool for prostate cancer.

The study was a cross-disciplinary collaborative effort of UC molecular epidemiologist Tianying Wu, MD, PhD, epigenetic expert and UC environmental health chair Shuk-Mei Ho, PhD, former UC environmental health post-doc Wang-Yee Tang, PhD, UC statistician Jeff Welge and Harvard cancer epidemiologist Edward Giovannucci, MD. Wu's postdoctoral fellow Palash Mallick, PhD, also contributed to the study.

Wu merged epidemiologic and molecular data from 22 studies conducted in the United States and Europe between 2000 and 2009. More than 2000 human biologic samples (1,635 prostate cancer cases and 573 controls) were analyzed for the current study, including whole blood, plasma, urine, ejaculates and other secretions.

Wu determined that GSTP1 was a statistically significant biomarker for prostate cancer and could increase the specificity of prostate cancer diagnosis by up to 70 percent as compared to using the PSA test alone.

"The PSA test is highly sensitive, but it cannot differentiate between prostate cancer and benign prostatic conditions such as benign prostatic hyperplasia, leading many men to have unnecessary biopsies," says Wu, lead author of the study and assistant professor of environmental health at UC.

"It is unlikely that we would find a marker that has the same sensitivity as PSA," she adds, "but finding a highly specific circulating biomarker like GSTP1 that complements the PSA test could greatly improve the accuracy of prostate cancer detection before recommending patients for an invasive biopsy."

Alterations of the DNA methylation process are commonly associated with cancerous tumor growth and changes can be detected in bodily fluids. GSTP1 DNA methylation is particularly associated with prostate cancer and can be detected in the bloodstream using high throughput standardized molecular biology techniques

"Measuring GSTPI in plasma or urine is an easy and non-invasive test. This biomarker will give physicians reassurance regards to whether to conduct biopsies in selected patients," adds Wu.


'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati Academic Health Center
Source:Eurekalert

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
3. The dietary supplement genistein can undermine breast cancer treatment
4. Saliva proteins could help detection of oral cancer
5. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
6. Breakthrough optical technology to assess colon cancer risk, accuracy
7. Breast cancer cells recycle to escape death by hormonal therapy
8. Nanodiamond drug device could transform cancer treatment
9. Second lumpectomy for breast cancer reduces survival rates
10. Study looks at psychological impact of gene test for breast cancer
11. SNM releases new fact sheet on breast cancer and molecular imaging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/1/2016)... 2016 Favorable Government Initiatives Coupled ... Criminal Identification to Boost Global Biometrics System Market Through ... Research report, " Global Biometrics Market By Type, ... Opportunities, 2011 - 2021", the global biometrics market is ... account of growing security concerns across various end use ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology: